Comparative Pharmacology
Head-to-head clinical analysis: BYDUREON versus PRANDIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYDUREON versus PRANDIN.
BYDUREON vs PRANDIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Repaglinide stimulates insulin secretion from pancreatic beta cells by binding to and closing ATP-sensitive potassium channels, leading to membrane depolarization and calcium influx.
2 mg subcutaneously once every 7 days (weekly).
0.5–4 mg orally 0–30 minutes before meals, typically 2–4 times daily. Maximum single dose: 4 mg. Maximum total daily dose: 16 mg.
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration for immediate-release exenatide; however, BYDUREON (extended-release) exhibits a prolonged half-life of approximately 2 weeks (mean range 14-20 days) due to encapsulation in microspheres.
Terminal elimination half-life: 1.0-1.5 hours. Clinically, due to rapid elimination, repaglinide requires dosing before each meal to control postprandial glucose.
Excreted primarily via renal proteolytic degradation; intact exenatide is eliminated renally. Renal clearance accounts for approximately 80% of total clearance; fecal elimination is negligible (<5%).
Primarily hepatic metabolism via CYP2C8 and CYP3A4; metabolites excreted in bile (90%) and urine (10%). Less than 0.1% excreted unchanged in urine.
Category C
Category C
Antidiabetic
Antidiabetic